Last updated: August 1, 2026
Pargyline hydrochloride is an obsolete monoamine oxidase inhibitor that has no identifiable active modern clinical-development program, no current U.S. FDA commercial status, and no meaningful branded pharmaceutical market. Its original antihypertensive use has been displaced by safer and more effective therapies. Commercial opportunity is limited to research chemicals, analytical standards, and potential academic repurposing rather than a conventional prescription-drug market.
What is the current clinical-trial status of pargyline hydrochloride?
No active late-stage or commercial clinical-development program for pargyline hydrochloride is listed in major public trial registries. Historical studies evaluated pargyline as an antihypertensive agent and monoamine oxidase inhibitor, but those studies predate current trial-registration practices and do not represent a current development pipeline.
| Development category |
Current status |
| Phase 1 studies |
No active modern program identified |
| Phase 2 studies |
No active modern program identified |
| Phase 3 studies |
None identified |
| Registration-enabling trials |
None identified |
| Approved U.S. indication |
No current FDA marketing status identified |
| Current branded product |
None identified |
| Biosimilar pathway |
Not applicable |
| Generic competition |
No active conventional generic market identified |
Pargyline irreversibly inhibits monoamine oxidase, with a relatively selective effect on monoamine oxidase B at lower exposure levels but clinically important monoamine oxidase A inhibition at higher concentrations. Its pharmacology creates interaction risks with sympathomimetic drugs, serotonergic medicines, certain opioids, and tyramine-containing foods. These safety issues reduced its suitability for chronic treatment.
The compound remains present in preclinical pharmacology. Researchers use it to inhibit monoamine oxidase activity in cellular and animal models, including studies involving dopamine metabolism, oxidative stress, neurodegeneration, and drug-metabolism pathways. That research use does not constitute a clinical-trial market.
What clinical uses were historically studied?
Historical clinical use centered on hypertension. Pargyline was also investigated for psychiatric and neurologic applications because monoamine oxidase inhibition increases concentrations of monoamine neurotransmitters. The drug did not establish a durable commercial position in those areas.
Current treatment standards have shifted to:
- Selective serotonin reuptake inhibitors and other antidepressants for depression.
- Reversible or selective monoamine oxidase inhibitors for narrowly defined psychiatric indications.
- Selegiline and rasagiline for Parkinson's disease.
- Multiple modern antihypertensive classes with better tolerability and more predictable dosing.
Pargyline has no established role in current treatment guidelines for hypertension, depression, or Parkinson's disease.
What is the FDA regulatory status of pargyline hydrochloride?
Pargyline hydrochloride is not an actively marketed FDA-approved product in the United States. It does not have a current commercial presence comparable with approved products listed in the FDA Orange Book or active Drugs@FDA product records.
The historical product Eutonyl, containing pargyline hydrochloride, was marketed for hypertension. Its commercial discontinuation reflects the loss of clinical and market relevance rather than a modern generic substitution event. There is no current FDA regulatory pathway supporting routine prescribing of pargyline hydrochloride in the United States.
| FDA issue |
Assessment |
| Current approved product |
None identified |
| Current Orange Book product listing |
None identified as an active marketed product |
| Current FDA exclusivity |
None |
| New drug exclusivity |
None |
| Orphan-drug exclusivity |
None |
| Pediatric exclusivity |
None |
| Reference-listed drug market |
None identified |
| Active ANDA market |
None identified |
An investigator seeking to develop pargyline hydrochloride today would generally need to establish an appropriate regulatory pathway, including manufacturing controls, nonclinical safety, clinical evidence, drug-interaction characterization, and a modern risk-management strategy.
When does pargyline hydrochloride lose patent and regulatory exclusivity?
Pargyline hydrochloride lost practical exclusivity decades ago. Its original composition-of-matter and product rights would have expired long before the current pharmaceutical patent framework became commercially relevant.
No commercially important unexpired composition patent, formulation patent, method-of-use patent, or manufacturing patent is publicly associated with pargyline hydrochloride as an active product. Any historical patents covering the compound, its salts, or early therapeutic uses are expected to be expired.
| IP category |
Current commercial position |
| Original compound patent |
Expired |
| Hydrochloride salt rights |
Expired or no longer commercially relevant |
| Original antihypertensive use |
Public domain |
| Modern formulation patents |
None identified |
| Delivery-system patents |
None identified |
| Method-of-use patents |
No active commercial estate identified |
| Manufacturing patents |
No current blocking estate identified |
The absence of a live patent estate does not eliminate regulatory barriers. A new sponsor would still need to demonstrate that the proposed product is safe, reproducibly manufactured, and clinically useful. For an old drug with known interaction risks and no established modern indication, those development costs would likely exceed the value of a conventional generic launch.
What formulations are protected by pargyline hydrochloride patents?
No active commercially significant formulation estate has been identified for pargyline hydrochloride. Historical use involved conventional oral dosage forms. There is no recognized long-acting injectable, transdermal, implantable, inhaled, or targeted-delivery platform associated with the compound.
A sponsor could potentially seek patents on a new formulation or delivery system if it generated a novel, non-obvious, and clinically meaningful benefit. Such patents would protect the new formulation rather than restore exclusivity to pargyline hydrochloride itself.
How strong is the patent estate for pargyline hydrochloride?
The patent estate is commercially weak.
Patent strength is limited by four factors:
- The underlying molecule is old and widely disclosed.
- Historical therapeutic uses are in the public domain.
- Conventional oral dosage forms would face substantial prior-art barriers.
- Clinical development would need to address known monoamine oxidase inhibitor risks.
A new patent strategy could focus on a narrowly defined use, combination, formulation, or delivery system. The probability of durable exclusivity would depend on new clinical data and claim scope. Broad claims covering monoamine oxidase inhibition, hypertension treatment, or conventional pargyline hydrochloride tablets would face significant validity and prior-art challenges.
Are there Paragraph IV challenges involving pargyline hydrochloride?
No current Paragraph IV litigation or active ANDA challenge involving pargyline hydrochloride has been identified.
Paragraph IV litigation requires a listed reference drug and an active generic-drug filing challenging relevant patents. Pargyline hydrochloride has no meaningful current Orange Book reference-product market, no identified active patent listing, and no visible generic dispute.
| Litigation question |
Status |
| Active Paragraph IV notice |
None identified |
| Hatch-Waxman litigation |
None identified |
| Patent-certification dispute |
None identified |
| ANDA exclusivity dispute |
None identified |
| 30-month stay |
Not applicable |
| Settlement agreement |
None identified |
A future applicant could still face FDA requirements for a new drug application, an abbreviated pathway if an appropriate reference product exists, or a regulatory determination that an alternative development route is necessary. The practical issue is regulatory eligibility, not patent clearance.
What generic entry risks exist for pargyline hydrochloride?
Patent-based generic-entry risk is minimal because no active commercial patent barrier has been identified. Market-entry risk is high for different reasons:
- Limited or absent physician demand.
- No active branded reference product.
- Safety concerns associated with irreversible monoamine oxidase inhibition.
- Small manufacturing volumes.
- Difficult commercial positioning against established therapies.
- Potential requirements for updated clinical and pharmacovigilance evidence.
A conventional generic launch would have little economic rationale unless a sponsor identified a validated niche indication, a supply shortage, or a research-use market with recurring demand.
What is the current market size for pargyline hydrochloride?
There is no reliable public prescription-sales market for pargyline hydrochloride. The product is commercially relevant mainly as a laboratory reagent, reference standard, or specialty research chemical.
| Market segment |
Commercial assessment |
| U.S. prescription market |
Effectively inactive |
| European prescription market |
No established active market identified |
| Emerging-market prescription market |
No material market identified |
| Hospital use |
Negligible |
| Academic research |
Small, recurring niche |
| CRO and laboratory use |
Small niche |
| Analytical reference standards |
Limited specialty demand |
| Consumer market |
Not established |
Research-use suppliers may sell pargyline or pargyline hydrochloride in small quantities. Those sales do not provide a basis for projecting a conventional pharmaceutical market measured in millions or billions of dollars.
What companies supply pargyline hydrochloride?
The supply base is composed primarily of chemical and life-science reagent vendors rather than branded pharmaceutical manufacturers. Suppliers can change by region, catalog status, purity grade, and regulatory classification. Product listings generally target research laboratories, not patients or pharmacies.
The relevant competitive factors are:
- Chemical purity.
- Certificate-of-analysis quality.
- Lot consistency.
- Packaging and storage.
- Global shipping controls.
- Availability of analytical standards.
- Compliance with research-use restrictions.
No company has an identifiable late-stage clinical or commercial prescription strategy for pargyline hydrochloride.
What is the projected market for pargyline hydrochloride?
The base-case pharmaceutical forecast is effectively zero or nominal through the medium term. The likely market remains a small research-chemical niche.
| Scenario |
Probability profile |
Commercial outcome |
| Base case |
Most likely |
Continued research-use sales with no prescription launch |
| Academic repurposing |
Low |
Limited investigator-sponsored studies |
| New clinical indication |
Very low |
Requires substantial safety and efficacy investment |
| Reformulated product |
Very low |
Possible only with a clear clinical advantage |
| Broad generic relaunch |
Very low |
Weak demand and high regulatory burden |
A conventional revenue forecast would be misleading because there is no established prescription baseline. The commercial ceiling is constrained by therapeutic substitution and safety management. A sponsor would need to create a new market through clinical differentiation rather than capture an existing pargyline market.
How does pargyline hydrochloride compare with current monoamine oxidase inhibitors?
Pargyline is disadvantaged against newer or more clinically targeted monoamine oxidase inhibitors.
| Product or class |
Main use |
Relative position versus pargyline |
| Selegiline |
Parkinson's disease; depression in selected formulations |
More established clinical positioning |
| Rasagiline |
Parkinson's disease |
Better-defined indication and dosing |
| Safinamide |
Parkinson's disease adjunct therapy |
Modern regulatory profile |
| Tranylcypromine |
Treatment-resistant depression |
Established psychiatric use despite interaction burden |
| Phenelzine |
Depression |
Established but safety-limited |
| Pargyline |
Historical hypertension treatment |
No current mainstream indication |
Pargyline's irreversible enzyme inhibition and interaction profile create a weaker risk-benefit proposition than agents developed for defined neurologic or psychiatric indications.
What manufacturing and intellectual-property barriers apply?
Chemical manufacturing is not the principal barrier. The molecule is structurally simple relative to many modern small-molecule drugs, and its synthesis is described in historical and chemical literature. The more important barriers are pharmaceutical quality, impurity control, salt characterization, stability, and regulatory documentation.
A commercial manufacturer would need to establish:
- GMP-compliant production.
- Validated analytical methods.
- Impurity and degradation-product controls.
- Batch reproducibility.
- Stability data.
- Appropriate packaging and labeling.
- Controlled interaction and contraindication information.
- Pharmacovigilance procedures if marketed clinically.
No active manufacturing patent barrier is apparent. Regulatory and market-access barriers are more significant than freedom-to-operate risk.
What licensing deals or partnerships involve pargyline hydrochloride?
No material current licensing deal, co-development agreement, or commercial partnership involving pargyline hydrochloride has been identified. The compound has no visible business-development activity comparable with active CNS, cardiovascular, or oncology assets.
Any future transaction would likely involve one of three structures:
- An academic repurposing collaboration.
- A research-reagent supply agreement.
- A niche formulation or specialty-market license.
A conventional pharmaceutical licensing deal would require new clinical evidence and a differentiated product profile.
Key Takeaways
- Pargyline hydrochloride has no active mainstream clinical-development program.
- The historical antihypertensive product has been discontinued.
- No current FDA-approved marketed product, Orange Book exclusivity, or active regulatory exclusivity has been identified.
- Original compound, salt, formulation, and historical-use rights are no longer commercially blocking.
- No active Paragraph IV dispute, Hatch-Waxman litigation, or settlement agreement is identified.
- Current demand is limited to research chemicals, laboratory studies, and analytical reference materials.
- The prescription market is effectively inactive.
- The medium-term commercial forecast is nominal unless a sponsor develops a new indication or clinically differentiated formulation.
- Manufacturing is technically feasible, but regulatory, safety, and commercial barriers are substantial.
- Pargyline is commercially weaker than selegiline, rasagiline, safinamide, phenelzine, and tranylcypromine because it lacks a current approved therapeutic niche.
FAQs
Is pargyline hydrochloride still prescribed for hypertension?
No. It is not an established current treatment for hypertension, which is now managed with safer and better-supported drug classes.
Is pargyline hydrochloride a monoamine oxidase inhibitor?
Yes. It is an irreversible monoamine oxidase inhibitor with effects that can produce clinically important interactions with serotonergic, sympathomimetic, opioid, and tyramine-containing substances.
Can pargyline hydrochloride be developed as a generic drug?
A sponsor would first need an appropriate regulatory pathway and reference product. The absence of an active commercial reference market makes a conventional generic strategy commercially unattractive.
Does pargyline hydrochloride have biosimilar competition?
No. Biosimilar rules apply to biologic products. Pargyline hydrochloride is a small-molecule chemical compound.
Is pargyline hydrochloride available for laboratory research?
It may be available from specialty chemical and life-science suppliers in research-use grades. Availability, purity, and shipment restrictions vary by jurisdiction and supplier.
References
-
ClinicalTrials.gov. (n.d.). ClinicalTrials.gov search results for pargyline. U.S. National Library of Medicine. https://clinicaltrials.gov/
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
National Center for Biotechnology Information. (n.d.). PubChem compound summary: Pargyline. PubChem. https://pubchem.ncbi.nlm.nih.gov/
-
National Library of Medicine. (n.d.). DailyMed drug labeling database. https://dailymed.nlm.nih.gov/
